[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fkHu08Jjv2dOHq7T3peeRIjAPVM4BRDOKZBx1gomIjCg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":86,"rows":93},"The University of Texas Medical Branch, Galveston",[4],251,false,47,24,40603,18,165,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Aging",12,{"name":18,"count":19},"Burns",11,{"name":21,"count":22},"Burn",10,{"name":24,"count":25},"Breast Cancer",9,{"name":27,"count":28},"Sarcopenia",8,{"name":30,"count":28},"Stroke",{"name":32,"count":33},"Traumatic Brain Injury",7,{"name":35,"count":36},"Obesity",6,[38,43,48,53,58,63,67,72,77,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02983461","Use of Sildenafil for Treatment of Urinary Incontinence","2020-03-01","Sildenafil",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT05880862","Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls","2025-12","Mirabegron",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT05815485","A Randomized, Double-Blind, Placebo-Controlled Phase 2\u002F3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia","2026-04","Azeliragon",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT05672927","Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)","2026-08","9-valent HPV vaccine, 2 doses alternate timing",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT06681207","Explore the Effects of Cortical Priming on Visuomotor Stepping Learning in Persons With Chronic Stroke","2026-08-30","anodal transcranial direct current stimulation",{"nctId":64,"briefTitle":65,"date":66,"intervention":62},"NCT06191549","Brain Stimulation Enhance Post-stroke Walking Survivors and Healthy Adults","2026-08-31",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT02935400","Acute Porphyria Biomarkers for Disease Activity","2026-12","Hemin",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT04565925","Sildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries","2026-12-01","Sildenafil Citrate",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT07203287","Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease","2026-12-31","Rocuronium",{"nctId":83,"briefTitle":84,"date":80,"intervention":85},"NCT06801626","Novel Strategies for Reducing Burn Scar Itch","Famotidine and 4% topical cromolyn sodium",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,136,163,181,199,217,235,307,328,352,380,409,427,453,473,496,514,542,565,631,676,708,742,781,805,823,847,875,893,911,929,957,975,993,1019,1045,1073,1100,1118,1136,1160,1185,1203,1221,1285,1307,1344,1366,1391,1422,1440,1458,1476,1494,1512,1536,1564,1582,1600,1618,1636,1662,1686,1704,1728,1746,1764,1782,1800,1818,1836,1858,1880,1919,1945,1963,1987,2011,2035,2061,2079,2102,2120,2143,2174,2192,2210,2255,2289,2314,2339,2363,2387,2410,2437,2455,2480,2503,2521,2544,2562,2580,2605,2629,2652,2676],{"intervention":95,"totalTrials":96,"cells":97},"9-valent HPV vaccine, 3 doses standard timing",2,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":134},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":133,"soonestReadout":56},[109,120],{"nctId":54,"briefTitle":55,"status":110,"phases":111,"primaryCompletion":56,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":119},"RECRUITING",[91],"2027-08","2023-01-18",618,[116,117,118],"Immunization","HPV Infection","Human Papillomavirus",[57,95],{"nctId":121,"briefTitle":122,"status":123,"phases":124,"primaryCompletion":125,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":131},"NCT03943875","GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose","COMPLETED",[91],"2025-01-13","2019-06-17",767,[116,129,130],"Efficacy","Human Papilloma Virus",[132,95],"9-valent HPV vaccine, 2 dose efficacy",1,{"trials":135,"activeCount":100},[],{"intervention":81,"totalTrials":133,"cells":137},{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":144,"PHASE4":146,"NA":161},{"trials":139,"activeCount":100},[],{"trials":141,"activeCount":100},[],{"trials":143,"activeCount":100},[],{"trials":145,"activeCount":100},[],{"trials":147,"activeCount":133,"soonestReadout":80},[148],{"nctId":78,"briefTitle":79,"status":110,"phases":149,"primaryCompletion":80,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":157},[91],"2027-08-26","2025-08-26",490,[154,155,156],"Post Operative Pulmonary Complications","Neuromuscular Blockade","General Anesthesia",[81,158,159,160],"Cisatracurium","Sugammadex","Neostigmine",{"trials":162,"activeCount":100},[],{"intervention":158,"totalTrials":133,"cells":164},{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":171,"PHASE4":173,"NA":179},{"trials":166,"activeCount":100},[],{"trials":168,"activeCount":100},[],{"trials":170,"activeCount":100},[],{"trials":172,"activeCount":100},[],{"trials":174,"activeCount":133,"soonestReadout":80},[175],{"nctId":78,"briefTitle":79,"status":110,"phases":176,"primaryCompletion":80,"completion":150,"start":151,"enrollment":152,"conditions":177,"interventions":178},[91],[154,155,156],[81,158,159,160],{"trials":180,"activeCount":100},[],{"intervention":159,"totalTrials":133,"cells":182},{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":187,"PHASE3":189,"PHASE4":191,"NA":197},{"trials":184,"activeCount":100},[],{"trials":186,"activeCount":100},[],{"trials":188,"activeCount":100},[],{"trials":190,"activeCount":100},[],{"trials":192,"activeCount":133,"soonestReadout":80},[193],{"nctId":78,"briefTitle":79,"status":110,"phases":194,"primaryCompletion":80,"completion":150,"start":151,"enrollment":152,"conditions":195,"interventions":196},[91],[154,155,156],[81,158,159,160],{"trials":198,"activeCount":100},[],{"intervention":160,"totalTrials":133,"cells":200},{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":215},{"trials":202,"activeCount":100},[],{"trials":204,"activeCount":100},[],{"trials":206,"activeCount":100},[],{"trials":208,"activeCount":100},[],{"trials":210,"activeCount":133,"soonestReadout":80},[211],{"nctId":78,"briefTitle":79,"status":110,"phases":212,"primaryCompletion":80,"completion":150,"start":151,"enrollment":152,"conditions":213,"interventions":214},[91],[154,155,156],[81,158,159,160],{"trials":216,"activeCount":100},[],{"intervention":57,"totalTrials":133,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":227,"NA":233},{"trials":220,"activeCount":100},[],{"trials":222,"activeCount":100},[],{"trials":224,"activeCount":100},[],{"trials":226,"activeCount":100},[],{"trials":228,"activeCount":133,"soonestReadout":56},[229],{"nctId":54,"briefTitle":55,"status":110,"phases":230,"primaryCompletion":56,"completion":112,"start":113,"enrollment":114,"conditions":231,"interventions":232},[91],[116,117,118],[57,95],{"trials":234,"activeCount":100},[],{"intervention":42,"totalTrials":36,"cells":236},{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":270,"PHASE3":272,"PHASE4":285,"NA":287},{"trials":238,"activeCount":100},[],{"trials":240,"activeCount":133,"soonestReadout":41},[241,249,260],{"nctId":39,"briefTitle":40,"status":242,"phases":243,"primaryCompletion":41,"completion":244,"start":245,"enrollment":9,"conditions":246,"interventions":248},"ACTIVE_NOT_RECRUITING",[88],"2027-07","2017-03-10",[247],"Urinary Incontinence",[42],{"nctId":250,"briefTitle":251,"status":252,"phases":253,"primaryCompletion":254,"completion":254,"start":255,"enrollment":100,"conditions":256,"interventions":259},"NCT02106871","Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer","WITHDRAWN",[88],"2017-06","2014-04",[257,258],"Pancreatic Cancer","Cholangiocarcinoma",[42],{"nctId":261,"briefTitle":262,"status":123,"phases":263,"primaryCompletion":264,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":268},"NCT02114775","Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI)",[88],"2017-11-10","2014-12-12",34,[32],[269,42],"Growth Hormone",{"trials":271,"activeCount":100},[],{"trials":273,"activeCount":133,"soonestReadout":279},[274],{"nctId":275,"briefTitle":276,"status":277,"phases":278,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":284},"NCT06800092","Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment","NOT_YET_RECRUITING",[89,90],"2030-06-01","2027-06-15",30,[283],"Cancer",[42],{"trials":286,"activeCount":100},[],{"trials":288,"activeCount":100},[289,299],{"nctId":290,"briefTitle":291,"status":123,"phases":292,"primaryCompletion":293,"completion":293,"start":294,"enrollment":281,"conditions":295,"interventions":297},"NCT01661595","The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue",[92],"2015-06","2012-11",[296],"Fatigue",[42,298],"tadalafil",{"nctId":300,"briefTitle":301,"status":123,"phases":302,"primaryCompletion":303,"completion":303,"start":304,"enrollment":16,"conditions":305,"interventions":306},"NCT01059994","Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability",[92],"2013-07","2010-01",[296,15],[42],{"intervention":52,"totalTrials":133,"cells":308},{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":315,"PHASE4":324,"NA":326},{"trials":310,"activeCount":100},[],{"trials":312,"activeCount":100},[],{"trials":314,"activeCount":100},[],{"trials":316,"activeCount":133,"soonestReadout":51},[317],{"nctId":49,"briefTitle":50,"status":242,"phases":318,"primaryCompletion":51,"completion":51,"start":319,"enrollment":320,"conditions":321,"interventions":323},[89,90],"2023-05-04",144,[322],"COVID-19",[52],{"trials":325,"activeCount":100},[],{"trials":327,"activeCount":100},[],{"intervention":85,"totalTrials":133,"cells":329},{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":348,"NA":350},{"trials":331,"activeCount":100},[],{"trials":333,"activeCount":100},[],{"trials":335,"activeCount":100},[],{"trials":337,"activeCount":133,"soonestReadout":80},[338],{"nctId":83,"briefTitle":84,"status":110,"phases":339,"primaryCompletion":80,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":347},[90],"2027-11-01","2025-03-01",44,[344,345,346],"Burn Scar","Itch Scarring","Wound",[85],{"trials":349,"activeCount":100},[],{"trials":351,"activeCount":100},[],{"intervention":353,"totalTrials":133,"cells":354},"Research Grade RG-RV",{"EARLY_PHASE1":355,"PHASE1":357,"PHASE2":359,"PHASE3":374,"PHASE4":376,"NA":378},{"trials":356,"activeCount":100},[],{"trials":358,"activeCount":100},[],{"trials":360,"activeCount":133,"soonestReadout":365},[361],{"nctId":362,"briefTitle":363,"status":110,"phases":364,"primaryCompletion":365,"completion":365,"start":366,"enrollment":367,"conditions":368,"interventions":373},"NCT05331170","Viral Mucosal Reprogramming",[89],"2027-05-01","2023-04-27",75,[369,370,371,372],"Asthma","Allergic Rhinitis","Cat Allergy","Healthy",[353],{"trials":375,"activeCount":100},[],{"trials":377,"activeCount":100},[],{"trials":379,"activeCount":100},[],{"intervention":381,"totalTrials":133,"cells":382},"Lidocaine",{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":403,"PHASE4":405,"NA":407},{"trials":384,"activeCount":100},[],{"trials":386,"activeCount":100},[],{"trials":388,"activeCount":133,"soonestReadout":393},[389],{"nctId":390,"briefTitle":391,"status":110,"phases":392,"primaryCompletion":393,"completion":112,"start":394,"enrollment":395,"conditions":396,"interventions":401},"NCT07294118","Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage",[89],"2027-06","2026-01-02",15,[397,398,399,400],"Subarachnoid Hemorrhage, Aneurysmal","Headache","Opiate Dependence","Opioid Use",[381,402],"Lidocaine and Dexamethasone",{"trials":404,"activeCount":100},[],{"trials":406,"activeCount":100},[],{"trials":408,"activeCount":100},[],{"intervention":402,"totalTrials":133,"cells":410},{"EARLY_PHASE1":411,"PHASE1":413,"PHASE2":415,"PHASE3":421,"PHASE4":423,"NA":425},{"trials":412,"activeCount":100},[],{"trials":414,"activeCount":100},[],{"trials":416,"activeCount":133,"soonestReadout":393},[417],{"nctId":390,"briefTitle":391,"status":110,"phases":418,"primaryCompletion":393,"completion":112,"start":394,"enrollment":395,"conditions":419,"interventions":420},[89],[397,398,399,400],[381,402],{"trials":422,"activeCount":100},[],{"trials":424,"activeCount":100},[],{"trials":426,"activeCount":100},[],{"intervention":428,"totalTrials":133,"cells":429},"Zepbound",{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":447,"PHASE4":449,"NA":451},{"trials":431,"activeCount":100},[],{"trials":433,"activeCount":100},[],{"trials":435,"activeCount":133,"soonestReadout":440},[436],{"nctId":437,"briefTitle":438,"status":110,"phases":439,"primaryCompletion":440,"completion":441,"start":442,"enrollment":443,"conditions":444,"interventions":446},"NCT07220473","Tirzepatide to Slow Biological Aging",[89],"2027-11","2028-01","2026-02-27",90,[15,445],"LONGEVITY 1",[428],{"trials":448,"activeCount":100},[],{"trials":450,"activeCount":100},[],{"trials":452,"activeCount":100},[],{"intervention":76,"totalTrials":133,"cells":454},{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":467,"PHASE4":469,"NA":471},{"trials":456,"activeCount":100},[],{"trials":458,"activeCount":100},[],{"trials":460,"activeCount":133,"soonestReadout":75},[461],{"nctId":73,"briefTitle":74,"status":110,"phases":462,"primaryCompletion":75,"completion":75,"start":463,"enrollment":9,"conditions":464,"interventions":466},[89],"2021-07-07",[465,247],"Spinal Cord Injuries",[76],{"trials":468,"activeCount":100},[],{"trials":470,"activeCount":100},[],{"trials":472,"activeCount":100},[],{"intervention":47,"totalTrials":133,"cells":474},{"EARLY_PHASE1":475,"PHASE1":486,"PHASE2":488,"PHASE3":490,"PHASE4":492,"NA":494},{"trials":476,"activeCount":133,"soonestReadout":46},[477],{"nctId":44,"briefTitle":45,"status":242,"phases":478,"primaryCompletion":46,"completion":46,"start":479,"enrollment":480,"conditions":481,"interventions":484},[87],"2023-09-28",48,[482,247,483],"Urinary Bladder, Overactive","Accidental Falls",[47,485],"Trospium Chloride",{"trials":487,"activeCount":100},[],{"trials":489,"activeCount":100},[],{"trials":491,"activeCount":100},[],{"trials":493,"activeCount":100},[],{"trials":495,"activeCount":100},[],{"intervention":485,"totalTrials":133,"cells":497},{"EARLY_PHASE1":498,"PHASE1":504,"PHASE2":506,"PHASE3":508,"PHASE4":510,"NA":512},{"trials":499,"activeCount":133,"soonestReadout":46},[500],{"nctId":44,"briefTitle":45,"status":242,"phases":501,"primaryCompletion":46,"completion":46,"start":479,"enrollment":480,"conditions":502,"interventions":503},[87],[482,247,483],[47,485],{"trials":505,"activeCount":100},[],{"trials":507,"activeCount":100},[],{"trials":509,"activeCount":100},[],{"trials":511,"activeCount":100},[],{"trials":513,"activeCount":100},[],{"intervention":62,"totalTrials":96,"cells":515},{"EARLY_PHASE1":516,"PHASE1":518,"PHASE2":520,"PHASE3":522,"PHASE4":524,"NA":526},{"trials":517,"activeCount":100},[],{"trials":519,"activeCount":100},[],{"trials":521,"activeCount":100},[],{"trials":523,"activeCount":100},[],{"trials":525,"activeCount":100},[],{"trials":527,"activeCount":96,"soonestReadout":61},[528,535],{"nctId":59,"briefTitle":60,"status":110,"phases":529,"primaryCompletion":61,"completion":530,"start":531,"enrollment":532,"conditions":533,"interventions":534},[92],"2026-10","2025-04-23",108,[30],[62],{"nctId":64,"briefTitle":65,"status":242,"phases":536,"primaryCompletion":66,"completion":66,"start":537,"enrollment":538,"conditions":539,"interventions":541},[92],"2025-05-01",70,[540],"Cerebral Vascular Accident",[62],{"intervention":71,"totalTrials":133,"cells":543},{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":548,"PHASE3":550,"PHASE4":552,"NA":554},{"trials":545,"activeCount":100},[],{"trials":547,"activeCount":100},[],{"trials":549,"activeCount":100},[],{"trials":551,"activeCount":100},[],{"trials":553,"activeCount":100},[],{"trials":555,"activeCount":133,"soonestReadout":70},[556],{"nctId":68,"briefTitle":69,"status":242,"phases":557,"primaryCompletion":70,"completion":80,"start":558,"enrollment":559,"conditions":560,"interventions":564},[],"2014-04-28",50,[561,562,563],"Acute Intermittent Porphyria","Hereditary Coproporphyria","Variegate Porphyria",[71],{"intervention":566,"totalTrials":567,"cells":568},"Testosterone",5,{"EARLY_PHASE1":569,"PHASE1":581,"PHASE2":612,"PHASE3":614,"PHASE4":616,"NA":629},{"trials":570,"activeCount":100},[571],{"nctId":572,"briefTitle":573,"status":574,"phases":575,"primaryCompletion":576,"completion":576,"start":577,"enrollment":578,"conditions":579,"interventions":580},"NCT02679274","Cycled Testosterone Therapy to Improve Physical Function in Frail Nursing Home Residents","TERMINATED",[87],"2016-09-20","2016-02-16",3,[15],[566],{"trials":582,"activeCount":100},[583,593,602],{"nctId":584,"briefTitle":585,"status":123,"phases":586,"primaryCompletion":587,"completion":587,"start":588,"enrollment":589,"conditions":590,"interventions":592},"NCT00957528","Cycled Testosterone Replacement Study",[88],"2008-12","2006-01",26,[591],"Hypogonadism",[566],{"nctId":594,"briefTitle":595,"status":123,"phases":596,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":600,"interventions":601},"NCT02990533","Muscle Anabolic Interventions to Accelerate Recovery From Hospitalization in Geriatric Patients",[88],"2020-11-08","2016-09",80,[15],[566],{"nctId":603,"briefTitle":604,"status":123,"phases":605,"primaryCompletion":606,"completion":607,"start":608,"enrollment":609,"conditions":610,"interventions":611},"NCT02203656","Feasibility Study of Post-hospitalization Interventions to Improve Physical Function in Older Adults",[88],"2016-07","2017-12","2013-10",113,[15],[566],{"trials":613,"activeCount":100},[],{"trials":615,"activeCount":100},[],{"trials":617,"activeCount":100},[618],{"nctId":619,"briefTitle":620,"status":123,"phases":621,"primaryCompletion":622,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":626},"NCT00957801","Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men",[91],"2015-12","2009-03",29,[27],[566,627,628],"Testosterone gel","Medrol",{"trials":630,"activeCount":100},[],{"intervention":632,"totalTrials":578,"cells":633},"Fenofibrate",{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":638,"PHASE3":640,"PHASE4":662,"NA":674},{"trials":635,"activeCount":100},[],{"trials":637,"activeCount":100},[],{"trials":639,"activeCount":100},[],{"trials":641,"activeCount":100},[642,652],{"nctId":643,"briefTitle":644,"status":252,"phases":645,"primaryCompletion":646,"completion":647,"start":648,"enrollment":100,"conditions":649,"interventions":650},"NCT00732485","Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate",[89,90],"2012-12","2013-12","2008-08",[21],[651],"fenofibrate",{"nctId":653,"briefTitle":654,"status":574,"phases":655,"primaryCompletion":656,"completion":657,"start":658,"enrollment":11,"conditions":659,"interventions":660},"NCT02452255","Fenofibrate and Propranolol in Burn Patients",[89,90],"2018-12","2019-07-12","2015-11",[21],[632,661],"Propranolol",{"trials":663,"activeCount":100},[664],{"nctId":665,"briefTitle":666,"status":574,"phases":667,"primaryCompletion":668,"completion":668,"start":669,"enrollment":578,"conditions":670,"interventions":672},"NCT01574131","Acute and Long-Term Outcome Investigations of Fenofibrate on Severely Burned Patients",[91],"2016-02","2012-05",[671],"Second or Third Degree Burns",[632,673],"Sugar Pill",{"trials":675,"activeCount":100},[],{"intervention":677,"totalTrials":96,"cells":678},"Sugar pill",{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":685,"PHASE4":700,"NA":706},{"trials":680,"activeCount":100},[],{"trials":682,"activeCount":100},[],{"trials":684,"activeCount":100},[],{"trials":686,"activeCount":100},[687],{"nctId":688,"briefTitle":689,"status":574,"phases":690,"primaryCompletion":691,"completion":692,"start":294,"enrollment":693,"conditions":694,"interventions":698},"NCT01666665","Mechanisms of Improved Wound Healing and Protein Synthesis of Insulin and Metformin",[89,90],"2018-08","2019-04-23",36,[695,696,697],"Insulin Resistance","Hypermetabolism","Hyperglycemia",[699,677],"Metformin",{"trials":701,"activeCount":100},[702],{"nctId":665,"briefTitle":666,"status":574,"phases":703,"primaryCompletion":668,"completion":668,"start":669,"enrollment":578,"conditions":704,"interventions":705},[91],[671],[632,673],{"trials":707,"activeCount":100},[],{"intervention":709,"totalTrials":96,"cells":710},"Testosterone enanthate",{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":715,"PHASE3":717,"PHASE4":730,"NA":740},{"trials":712,"activeCount":100},[],{"trials":714,"activeCount":100},[],{"trials":716,"activeCount":100},[],{"trials":718,"activeCount":100},[719],{"nctId":720,"briefTitle":721,"status":252,"phases":722,"primaryCompletion":723,"completion":724,"start":725,"enrollment":100,"conditions":726,"interventions":728},"NCT03674320","Cycled Testosterone Administration During Pulmonary Rehabilitation in Early Stage COPD",[89,90],"2024-08-01","2024-12-01","2021-12-01",[727],"COPD",[729],"Testosterone Enanthate",{"trials":731,"activeCount":100},[732],{"nctId":733,"briefTitle":734,"status":252,"phases":735,"primaryCompletion":736,"completion":607,"start":737,"enrollment":100,"conditions":738,"interventions":739},"NCT01417364","The Effects of Long Term Cyclic Testosterone Administration on Muscle Function and Bone in Older Men",[91],"2016-12","2016-01",[27],[709,709],{"trials":741,"activeCount":100},[],{"intervention":743,"totalTrials":96,"cells":744},"Ferrous sulfate",{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":749,"PHASE3":751,"PHASE4":753,"NA":779},{"trials":746,"activeCount":100},[],{"trials":748,"activeCount":100},[],{"trials":750,"activeCount":100},[],{"trials":752,"activeCount":100},[],{"trials":754,"activeCount":100},[755,766],{"nctId":756,"briefTitle":757,"status":574,"phases":758,"primaryCompletion":759,"completion":759,"start":760,"enrollment":761,"conditions":762,"interventions":765},"NCT04594070","Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy",[91],"2024-01-12","2020-10-27",14,[763,764],"Pregnancy Related","Iron Deficiency Anemia of Pregnancy",[743],{"nctId":767,"briefTitle":768,"status":123,"phases":769,"primaryCompletion":770,"completion":771,"start":772,"enrollment":773,"conditions":774,"interventions":777},"NCT05047211","Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia",[91],"2023-03-15","2023-04-15","2021-10-07",40,[775,776],"Anemia, Iron Deficiency","Delivery Complication",[743,778],"Iron dextran",{"trials":780,"activeCount":100},[],{"intervention":782,"totalTrials":133,"cells":783},"Recombinant human growth hormone",{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":790,"PHASE4":792,"NA":803},{"trials":785,"activeCount":100},[],{"trials":787,"activeCount":100},[],{"trials":789,"activeCount":100},[],{"trials":791,"activeCount":100},[],{"trials":793,"activeCount":100},[794],{"nctId":795,"briefTitle":796,"status":123,"phases":797,"primaryCompletion":798,"completion":798,"start":799,"enrollment":395,"conditions":800,"interventions":802},"NCT00957671","Anterior Pituitary Hormone Replacement in Traumatic Brain Injury",[91],"2015-10","2003-11",[801,32],"Growth Hormone Deficiency",[782],{"trials":804,"activeCount":100},[],{"intervention":132,"totalTrials":133,"cells":806},{"EARLY_PHASE1":807,"PHASE1":809,"PHASE2":811,"PHASE3":813,"PHASE4":815,"NA":821},{"trials":808,"activeCount":100},[],{"trials":810,"activeCount":100},[],{"trials":812,"activeCount":100},[],{"trials":814,"activeCount":100},[],{"trials":816,"activeCount":100},[817],{"nctId":121,"briefTitle":122,"status":123,"phases":818,"primaryCompletion":125,"completion":125,"start":126,"enrollment":127,"conditions":819,"interventions":820},[91],[116,129,130],[132,95],{"trials":822,"activeCount":100},[],{"intervention":824,"totalTrials":133,"cells":825},"Bupropion SR",{"EARLY_PHASE1":826,"PHASE1":828,"PHASE2":830,"PHASE3":832,"PHASE4":834,"NA":845},{"trials":827,"activeCount":100},[],{"trials":829,"activeCount":100},[],{"trials":831,"activeCount":100},[],{"trials":833,"activeCount":100},[],{"trials":835,"activeCount":100},[836],{"nctId":837,"briefTitle":838,"status":123,"phases":839,"primaryCompletion":736,"completion":736,"start":840,"enrollment":841,"conditions":842,"interventions":844},"NCT01390246","Bupropion for Smoking Cessation During Pregnancy",[91],"2011-07",65,[763,843],"Tobacco Use Disorder",[824],{"trials":846,"activeCount":100},[],{"intervention":848,"totalTrials":133,"cells":849},"Intravenous acetominophen",{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":856,"PHASE4":858,"NA":873},{"trials":851,"activeCount":100},[],{"trials":853,"activeCount":100},[],{"trials":855,"activeCount":100},[],{"trials":857,"activeCount":100},[],{"trials":859,"activeCount":100},[860],{"nctId":861,"briefTitle":862,"status":123,"phases":863,"primaryCompletion":254,"completion":864,"start":865,"enrollment":866,"conditions":867,"interventions":869},"NCT02922985","Multimodal Pain Management for Cesarean Delivery",[91],"2017-07","2016-10",120,[868],"Pain",[848,870,871,872],"Ketorolac, intramuscular","Bupivacaine, subcutaneous","Normal saline",{"trials":874,"activeCount":100},[],{"intervention":870,"totalTrials":133,"cells":876},{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":881,"PHASE3":883,"PHASE4":885,"NA":891},{"trials":878,"activeCount":100},[],{"trials":880,"activeCount":100},[],{"trials":882,"activeCount":100},[],{"trials":884,"activeCount":100},[],{"trials":886,"activeCount":100},[887],{"nctId":861,"briefTitle":862,"status":123,"phases":888,"primaryCompletion":254,"completion":864,"start":865,"enrollment":866,"conditions":889,"interventions":890},[91],[868],[848,870,871,872],{"trials":892,"activeCount":100},[],{"intervention":871,"totalTrials":133,"cells":894},{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":899,"PHASE3":901,"PHASE4":903,"NA":909},{"trials":896,"activeCount":100},[],{"trials":898,"activeCount":100},[],{"trials":900,"activeCount":100},[],{"trials":902,"activeCount":100},[],{"trials":904,"activeCount":100},[905],{"nctId":861,"briefTitle":862,"status":123,"phases":906,"primaryCompletion":254,"completion":864,"start":865,"enrollment":866,"conditions":907,"interventions":908},[91],[868],[848,870,871,872],{"trials":910,"activeCount":100},[],{"intervention":872,"totalTrials":133,"cells":912},{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":917,"PHASE3":919,"PHASE4":921,"NA":927},{"trials":914,"activeCount":100},[],{"trials":916,"activeCount":100},[],{"trials":918,"activeCount":100},[],{"trials":920,"activeCount":100},[],{"trials":922,"activeCount":100},[923],{"nctId":861,"briefTitle":862,"status":123,"phases":924,"primaryCompletion":254,"completion":864,"start":865,"enrollment":866,"conditions":925,"interventions":926},[91],[868],[848,870,871,872],{"trials":928,"activeCount":100},[],{"intervention":930,"totalTrials":133,"cells":931},"Vicryl-plus, monocryl-plus, PDS-plus",{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":938,"PHASE4":940,"NA":955},{"trials":933,"activeCount":100},[],{"trials":935,"activeCount":100},[],{"trials":937,"activeCount":100},[],{"trials":939,"activeCount":100},[],{"trials":941,"activeCount":100},[942],{"nctId":943,"briefTitle":944,"status":123,"phases":945,"primaryCompletion":946,"completion":946,"start":947,"enrollment":948,"conditions":949,"interventions":954},"NCT03386240","Antibacterial-coated Sutures at Time of Cesarean",[91],"2024-11-22","2018-01-09",1122,[950,951,952,953],"Surgical Site Infection","Surgical Wound Infection","Cesarean Section; Infection","Cesarean Section Complications",[930],{"trials":956,"activeCount":100},[],{"intervention":627,"totalTrials":133,"cells":958},{"EARLY_PHASE1":959,"PHASE1":961,"PHASE2":963,"PHASE3":965,"PHASE4":967,"NA":973},{"trials":960,"activeCount":100},[],{"trials":962,"activeCount":100},[],{"trials":964,"activeCount":100},[],{"trials":966,"activeCount":100},[],{"trials":968,"activeCount":100},[969],{"nctId":619,"briefTitle":620,"status":123,"phases":970,"primaryCompletion":622,"completion":622,"start":623,"enrollment":624,"conditions":971,"interventions":972},[91],[27],[566,627,628],{"trials":974,"activeCount":100},[],{"intervention":628,"totalTrials":133,"cells":976},{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":981,"PHASE3":983,"PHASE4":985,"NA":991},{"trials":978,"activeCount":100},[],{"trials":980,"activeCount":100},[],{"trials":982,"activeCount":100},[],{"trials":984,"activeCount":100},[],{"trials":986,"activeCount":100},[987],{"nctId":619,"briefTitle":620,"status":123,"phases":988,"primaryCompletion":622,"completion":622,"start":623,"enrollment":624,"conditions":989,"interventions":990},[91],[27],[566,627,628],{"trials":992,"activeCount":100},[],{"intervention":994,"totalTrials":133,"cells":995},"Caduet Pill",{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1002,"PHASE4":1004,"NA":1017},{"trials":997,"activeCount":100},[],{"trials":999,"activeCount":100},[],{"trials":1001,"activeCount":100},[],{"trials":1003,"activeCount":100},[],{"trials":1005,"activeCount":100},[1006],{"nctId":1007,"briefTitle":1008,"status":123,"phases":1009,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":1013,"conditions":1014,"interventions":1016},"NCT03504735","Caduet and TLC Intervention in Metabolic Syndrome",[91],"2009-01-01","2016-02-28","2005-05-01",53,[1015],"Metabolic Syndrome",[994],{"trials":1018,"activeCount":100},[],{"intervention":1020,"totalTrials":133,"cells":1021},"Oxytocin",{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1026,"PHASE3":1028,"PHASE4":1030,"NA":1043},{"trials":1023,"activeCount":100},[],{"trials":1025,"activeCount":100},[],{"trials":1027,"activeCount":100},[],{"trials":1029,"activeCount":100},[],{"trials":1031,"activeCount":100},[1032],{"nctId":1033,"briefTitle":1034,"status":123,"phases":1035,"primaryCompletion":1036,"completion":1037,"start":1038,"enrollment":1039,"conditions":1040,"interventions":1042},"NCT05782816","Low-Dose Versus High-Dose Oxytocin Dosing for Induction and Augmentation of Labor",[91],"2024-12-31","2025-06-24","2023-04-17",170,[1041],"Labor Long",[1020,1020],{"trials":1044,"activeCount":100},[],{"intervention":1046,"totalTrials":133,"cells":1047},"ReliaTect™ Post-Op Dressing",{"EARLY_PHASE1":1048,"PHASE1":1050,"PHASE2":1052,"PHASE3":1054,"PHASE4":1056,"NA":1071},{"trials":1049,"activeCount":100},[],{"trials":1051,"activeCount":100},[],{"trials":1053,"activeCount":100},[],{"trials":1055,"activeCount":100},[],{"trials":1057,"activeCount":100},[1058],{"nctId":1059,"briefTitle":1060,"status":123,"phases":1061,"primaryCompletion":1062,"completion":1063,"start":1064,"enrollment":1065,"conditions":1066,"interventions":1070},"NCT03887299","Antimicrobial Dressing Versus Standard Dressing in Obese Women Undergoing Cesarean Delivery",[91],"2020-01-18","2020-02-28","2019-04-18",154,[953,1067,1068,1069,951],"Wound Breakdown","Wound Infection","Satisfaction",[1046],{"trials":1072,"activeCount":100},[],{"intervention":1074,"totalTrials":133,"cells":1075},"DPP4 inhibitor",{"EARLY_PHASE1":1076,"PHASE1":1078,"PHASE2":1080,"PHASE3":1082,"PHASE4":1084,"NA":1098},{"trials":1077,"activeCount":100},[],{"trials":1079,"activeCount":100},[],{"trials":1081,"activeCount":100},[],{"trials":1083,"activeCount":100},[],{"trials":1085,"activeCount":100},[1086],{"nctId":1087,"briefTitle":1088,"status":574,"phases":1089,"primaryCompletion":1090,"completion":1090,"start":1091,"enrollment":567,"conditions":1092,"interventions":1095},"NCT02365233","Fatty Liver Study in Patients With Type II Diabetes",[91],"2016-12-31","2013-05-01",[1093,1094],"Type II Diabetes","Nonalcoholic Fatty Liver",[1074,1096,1097],"Pioglitazone","Lantus insulin",{"trials":1099,"activeCount":100},[],{"intervention":1096,"totalTrials":133,"cells":1101},{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1108,"PHASE4":1110,"NA":1116},{"trials":1103,"activeCount":100},[],{"trials":1105,"activeCount":100},[],{"trials":1107,"activeCount":100},[],{"trials":1109,"activeCount":100},[],{"trials":1111,"activeCount":100},[1112],{"nctId":1087,"briefTitle":1088,"status":574,"phases":1113,"primaryCompletion":1090,"completion":1090,"start":1091,"enrollment":567,"conditions":1114,"interventions":1115},[91],[1093,1094],[1074,1096,1097],{"trials":1117,"activeCount":100},[],{"intervention":1097,"totalTrials":133,"cells":1119},{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1126,"PHASE4":1128,"NA":1134},{"trials":1121,"activeCount":100},[],{"trials":1123,"activeCount":100},[],{"trials":1125,"activeCount":100},[],{"trials":1127,"activeCount":100},[],{"trials":1129,"activeCount":100},[1130],{"nctId":1087,"briefTitle":1088,"status":574,"phases":1131,"primaryCompletion":1090,"completion":1090,"start":1091,"enrollment":567,"conditions":1132,"interventions":1133},[91],[1093,1094],[1074,1096,1097],{"trials":1135,"activeCount":100},[],{"intervention":1137,"totalTrials":133,"cells":1138},"Postmenopausal, topical vaginal estrogen cream",{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1143,"PHASE3":1145,"PHASE4":1147,"NA":1158},{"trials":1140,"activeCount":100},[],{"trials":1142,"activeCount":100},[],{"trials":1144,"activeCount":100},[],{"trials":1146,"activeCount":100},[],{"trials":1148,"activeCount":100},[1149],{"nctId":1150,"briefTitle":1151,"status":574,"phases":1152,"primaryCompletion":1153,"completion":1153,"start":1154,"enrollment":33,"conditions":1155,"interventions":1157},"NCT01886794","Hormonal Status on Blood Flow and Tissue in Pelvic Organ Prolapse",[91],"2023-12-11","2013-06-06",[1156],"Pelvic Floor Disorders",[1137],{"trials":1159,"activeCount":100},[],{"intervention":1161,"totalTrials":133,"cells":1162},"Tranexamic acid",{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1167,"PHASE3":1169,"PHASE4":1171,"NA":1183},{"trials":1164,"activeCount":100},[],{"trials":1166,"activeCount":100},[],{"trials":1168,"activeCount":100},[],{"trials":1170,"activeCount":100},[],{"trials":1172,"activeCount":100},[1173],{"nctId":1174,"briefTitle":1175,"status":252,"phases":1176,"primaryCompletion":1177,"completion":1177,"start":1178,"enrollment":100,"conditions":1179,"interventions":1181},"NCT06419075","Tranexamic Acid in Vaginal Reconstructive Surgery",[91],"2025-01-27","2024-07-01",[1180],"Pelvic Organ Prolapse",[1161,1182],"Vasopressin",{"trials":1184,"activeCount":100},[],{"intervention":1182,"totalTrials":133,"cells":1186},{"EARLY_PHASE1":1187,"PHASE1":1189,"PHASE2":1191,"PHASE3":1193,"PHASE4":1195,"NA":1201},{"trials":1188,"activeCount":100},[],{"trials":1190,"activeCount":100},[],{"trials":1192,"activeCount":100},[],{"trials":1194,"activeCount":100},[],{"trials":1196,"activeCount":100},[1197],{"nctId":1174,"briefTitle":1175,"status":252,"phases":1198,"primaryCompletion":1177,"completion":1177,"start":1178,"enrollment":100,"conditions":1199,"interventions":1200},[91],[1180],[1161,1182],{"trials":1202,"activeCount":100},[],{"intervention":778,"totalTrials":133,"cells":1204},{"EARLY_PHASE1":1205,"PHASE1":1207,"PHASE2":1209,"PHASE3":1211,"PHASE4":1213,"NA":1219},{"trials":1206,"activeCount":100},[],{"trials":1208,"activeCount":100},[],{"trials":1210,"activeCount":100},[],{"trials":1212,"activeCount":100},[],{"trials":1214,"activeCount":100},[1215],{"nctId":767,"briefTitle":768,"status":123,"phases":1216,"primaryCompletion":770,"completion":771,"start":772,"enrollment":773,"conditions":1217,"interventions":1218},[91],[775,776],[743,778],{"trials":1220,"activeCount":100},[],{"intervention":661,"totalTrials":567,"cells":1222},{"EARLY_PHASE1":1223,"PHASE1":1225,"PHASE2":1227,"PHASE3":1229,"PHASE4":1281,"NA":1283},{"trials":1224,"activeCount":100},[],{"trials":1226,"activeCount":100},[],{"trials":1228,"activeCount":100},[],{"trials":1230,"activeCount":100},[1231,1246,1253,1257,1274],{"nctId":1232,"briefTitle":1233,"status":574,"phases":1234,"primaryCompletion":1235,"completion":1236,"start":1237,"enrollment":1238,"conditions":1239,"interventions":1240},"NCT00675714","Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation",[89,90],"2018-09","2019-07-15","2004-01",1126,[18],[1241,1242,1243,661,1244,1245],"Humatrope","Ketoconazole","Oxandrolone","Oxandrolone and propranolol combined","Humatrope and propranolol combined",{"nctId":1247,"briefTitle":1248,"status":574,"phases":1249,"primaryCompletion":656,"completion":692,"start":647,"enrollment":1250,"conditions":1251,"interventions":1252},"NCT01957449","Propranolol in Severely Burned Children",[89,90],63,[21],[661],{"nctId":653,"briefTitle":654,"status":574,"phases":1254,"primaryCompletion":656,"completion":657,"start":658,"enrollment":11,"conditions":1255,"interventions":1256},[89,90],[21],[632,661],{"nctId":1258,"briefTitle":1259,"status":123,"phases":1260,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1264,"conditions":1265,"interventions":1266},"NCT00673309","Assessment of Mechanisms of Improved Wound Healing",[89,90],"2011-04","2013-04","2000-07",644,[18],[1267,1268,661,269,1269,1270,1271,1272,1273],"Insulin High Dose","oxandrolone","Insulin Low Dose","IGF-1\u002FIGFBP-3","Itraconazole","Growth Hormone and Propranolol","Oxandrolone and Propranolol",{"nctId":1275,"briefTitle":1276,"status":574,"phases":1277,"primaryCompletion":1278,"completion":657,"start":303,"enrollment":8,"conditions":1279,"interventions":1280},"NCT01902810","Protective Effects of Propranolol in Adults",[89,90],"2019-06",[21],[661],{"trials":1282,"activeCount":100},[],{"trials":1284,"activeCount":100},[],{"intervention":1243,"totalTrials":96,"cells":1286},{"EARLY_PHASE1":1287,"PHASE1":1289,"PHASE2":1291,"PHASE3":1293,"PHASE4":1303,"NA":1305},{"trials":1288,"activeCount":100},[],{"trials":1290,"activeCount":100},[],{"trials":1292,"activeCount":100},[],{"trials":1294,"activeCount":100},[1295,1299],{"nctId":1232,"briefTitle":1233,"status":574,"phases":1296,"primaryCompletion":1235,"completion":1236,"start":1237,"enrollment":1238,"conditions":1297,"interventions":1298},[89,90],[18],[1241,1242,1243,661,1244,1245],{"nctId":1258,"briefTitle":1259,"status":123,"phases":1300,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1264,"conditions":1301,"interventions":1302},[89,90],[18],[1267,1268,661,269,1269,1270,1271,1272,1273],{"trials":1304,"activeCount":100},[],{"trials":1306,"activeCount":100},[],{"intervention":1308,"totalTrials":96,"cells":1309},"Somatropin",{"EARLY_PHASE1":1310,"PHASE1":1312,"PHASE2":1314,"PHASE3":1316,"PHASE4":1340,"NA":1342},{"trials":1311,"activeCount":100},[],{"trials":1313,"activeCount":100},[],{"trials":1315,"activeCount":100},[],{"trials":1317,"activeCount":100},[1318,1330],{"nctId":1319,"briefTitle":1320,"status":123,"phases":1321,"primaryCompletion":1322,"completion":1323,"start":1324,"enrollment":1325,"conditions":1326,"interventions":1328},"NCT03038594","Growth Hormone Therapy for Muscle Regeneration in Severely Burned Patients",[89,90],"2021-11-02","2021-11-30","2015-11-01",13,[18,1327],"Growth Hormone Treatment",[1308,1329],"0.09% Saline Solution",{"nctId":1331,"briefTitle":1332,"status":123,"phases":1333,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":1336,"conditions":1337,"interventions":1339},"NCT03554265","Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy",[90],"2023-10-04","2018-08-06",72,[32,296,1338,322],"Cognitive Impairment",[1308],{"trials":1341,"activeCount":100},[],{"trials":1343,"activeCount":100},[],{"intervention":269,"totalTrials":96,"cells":1345},{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1354,"PHASE3":1356,"PHASE4":1362,"NA":1364},{"trials":1347,"activeCount":100},[],{"trials":1349,"activeCount":100},[1350],{"nctId":261,"briefTitle":262,"status":123,"phases":1351,"primaryCompletion":264,"completion":264,"start":265,"enrollment":266,"conditions":1352,"interventions":1353},[88],[32],[269,42],{"trials":1355,"activeCount":100},[],{"trials":1357,"activeCount":100},[1358],{"nctId":1258,"briefTitle":1259,"status":123,"phases":1359,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1264,"conditions":1360,"interventions":1361},[89,90],[18],[1267,1268,661,269,1269,1270,1271,1272,1273],{"trials":1363,"activeCount":100},[],{"trials":1365,"activeCount":100},[],{"intervention":1367,"totalTrials":133,"cells":1368},"Vitamin E",{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1373,"PHASE3":1375,"PHASE4":1387,"NA":1389},{"trials":1370,"activeCount":100},[],{"trials":1372,"activeCount":100},[],{"trials":1374,"activeCount":100},[],{"trials":1376,"activeCount":100},[1377],{"nctId":1378,"briefTitle":1379,"status":123,"phases":1380,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":1385,"interventions":1386},"NCT01749371","Vitamin E Supplementation in Burned Patients",[89,90],"2017-08","2017-09","2013-02",31,[21],[1367],{"trials":1388,"activeCount":100},[],{"trials":1390,"activeCount":100},[],{"intervention":1392,"totalTrials":133,"cells":1393},"Hydrochlorothiazide 50mg",{"EARLY_PHASE1":1394,"PHASE1":1396,"PHASE2":1398,"PHASE3":1400,"PHASE4":1418,"NA":1420},{"trials":1395,"activeCount":100},[],{"trials":1397,"activeCount":100},[],{"trials":1399,"activeCount":100},[],{"trials":1401,"activeCount":100},[1402],{"nctId":1403,"briefTitle":1404,"status":1405,"phases":1406,"primaryCompletion":1407,"completion":1407,"start":1408,"enrollment":1409,"conditions":1410,"interventions":1417},"NCT03298802","Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide","UNKNOWN",[90],"2024-08-30","2017-11-21",612,[1411,1412,1413,1414,1415,1416],"Pre-Eclampsia","Gestational Hypertension","Superimposed Pre-Eclampsia","Hypertension, Pregnancy-Induced","Postpartum Pregnancy-Induced Hypertension","Postpartum Preeclampsia",[1392],{"trials":1419,"activeCount":100},[],{"trials":1421,"activeCount":100},[],{"intervention":1241,"totalTrials":133,"cells":1423},{"EARLY_PHASE1":1424,"PHASE1":1426,"PHASE2":1428,"PHASE3":1430,"PHASE4":1436,"NA":1438},{"trials":1425,"activeCount":100},[],{"trials":1427,"activeCount":100},[],{"trials":1429,"activeCount":100},[],{"trials":1431,"activeCount":100},[1432],{"nctId":1232,"briefTitle":1233,"status":574,"phases":1433,"primaryCompletion":1235,"completion":1236,"start":1237,"enrollment":1238,"conditions":1434,"interventions":1435},[89,90],[18],[1241,1242,1243,661,1244,1245],{"trials":1437,"activeCount":100},[],{"trials":1439,"activeCount":100},[],{"intervention":1242,"totalTrials":133,"cells":1441},{"EARLY_PHASE1":1442,"PHASE1":1444,"PHASE2":1446,"PHASE3":1448,"PHASE4":1454,"NA":1456},{"trials":1443,"activeCount":100},[],{"trials":1445,"activeCount":100},[],{"trials":1447,"activeCount":100},[],{"trials":1449,"activeCount":100},[1450],{"nctId":1232,"briefTitle":1233,"status":574,"phases":1451,"primaryCompletion":1235,"completion":1236,"start":1237,"enrollment":1238,"conditions":1452,"interventions":1453},[89,90],[18],[1241,1242,1243,661,1244,1245],{"trials":1455,"activeCount":100},[],{"trials":1457,"activeCount":100},[],{"intervention":1244,"totalTrials":133,"cells":1459},{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1464,"PHASE3":1466,"PHASE4":1472,"NA":1474},{"trials":1461,"activeCount":100},[],{"trials":1463,"activeCount":100},[],{"trials":1465,"activeCount":100},[],{"trials":1467,"activeCount":100},[1468],{"nctId":1232,"briefTitle":1233,"status":574,"phases":1469,"primaryCompletion":1235,"completion":1236,"start":1237,"enrollment":1238,"conditions":1470,"interventions":1471},[89,90],[18],[1241,1242,1243,661,1244,1245],{"trials":1473,"activeCount":100},[],{"trials":1475,"activeCount":100},[],{"intervention":1245,"totalTrials":133,"cells":1477},{"EARLY_PHASE1":1478,"PHASE1":1480,"PHASE2":1482,"PHASE3":1484,"PHASE4":1490,"NA":1492},{"trials":1479,"activeCount":100},[],{"trials":1481,"activeCount":100},[],{"trials":1483,"activeCount":100},[],{"trials":1485,"activeCount":100},[1486],{"nctId":1232,"briefTitle":1233,"status":574,"phases":1487,"primaryCompletion":1235,"completion":1236,"start":1237,"enrollment":1238,"conditions":1488,"interventions":1489},[89,90],[18],[1241,1242,1243,661,1244,1245],{"trials":1491,"activeCount":100},[],{"trials":1493,"activeCount":100},[],{"intervention":699,"totalTrials":133,"cells":1495},{"EARLY_PHASE1":1496,"PHASE1":1498,"PHASE2":1500,"PHASE3":1502,"PHASE4":1508,"NA":1510},{"trials":1497,"activeCount":100},[],{"trials":1499,"activeCount":100},[],{"trials":1501,"activeCount":100},[],{"trials":1503,"activeCount":100},[1504],{"nctId":688,"briefTitle":689,"status":574,"phases":1505,"primaryCompletion":691,"completion":692,"start":294,"enrollment":693,"conditions":1506,"interventions":1507},[89,90],[695,696,697],[699,677],{"trials":1509,"activeCount":100},[],{"trials":1511,"activeCount":100},[],{"intervention":1513,"totalTrials":133,"cells":1514},"Sulfamylon 5% and Silver Nitrate Soaks",{"EARLY_PHASE1":1515,"PHASE1":1517,"PHASE2":1519,"PHASE3":1521,"PHASE4":1532,"NA":1534},{"trials":1516,"activeCount":100},[],{"trials":1518,"activeCount":100},[],{"trials":1520,"activeCount":100},[],{"trials":1522,"activeCount":100},[1523],{"nctId":1524,"briefTitle":1525,"status":574,"phases":1526,"primaryCompletion":1527,"completion":1527,"start":1528,"enrollment":1529,"conditions":1530,"interventions":1531},"NCT00675922","Study of the Treatment of Burn Wounds With Antimicrobial Topical Soaks",[89,90],"2008-05","1995-07",98,[21],[1513],{"trials":1533,"activeCount":100},[],{"trials":1535,"activeCount":100},[],{"intervention":1537,"totalTrials":133,"cells":1538},"Azithromycin",{"EARLY_PHASE1":1539,"PHASE1":1541,"PHASE2":1543,"PHASE3":1545,"PHASE4":1560,"NA":1562},{"trials":1540,"activeCount":100},[],{"trials":1542,"activeCount":100},[],{"trials":1544,"activeCount":100},[],{"trials":1546,"activeCount":100},[1547],{"nctId":1548,"briefTitle":1549,"status":574,"phases":1550,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":1553,"conditions":1554,"interventions":1556},"NCT03060473","Treatment of ppROM With Erythromycin vs. Azithromycin Trial",[90],"2023-12-08","2017-02-23",21,[1555],"Preterm Premature Rupture of Membranes (PPROM)",[1537,1557,1558,1559],"Erythromycin","Ampicillin","Amoxicillin",{"trials":1561,"activeCount":100},[],{"trials":1563,"activeCount":100},[],{"intervention":1557,"totalTrials":133,"cells":1565},{"EARLY_PHASE1":1566,"PHASE1":1568,"PHASE2":1570,"PHASE3":1572,"PHASE4":1578,"NA":1580},{"trials":1567,"activeCount":100},[],{"trials":1569,"activeCount":100},[],{"trials":1571,"activeCount":100},[],{"trials":1573,"activeCount":100},[1574],{"nctId":1548,"briefTitle":1549,"status":574,"phases":1575,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":1553,"conditions":1576,"interventions":1577},[90],[1555],[1537,1557,1558,1559],{"trials":1579,"activeCount":100},[],{"trials":1581,"activeCount":100},[],{"intervention":1558,"totalTrials":133,"cells":1583},{"EARLY_PHASE1":1584,"PHASE1":1586,"PHASE2":1588,"PHASE3":1590,"PHASE4":1596,"NA":1598},{"trials":1585,"activeCount":100},[],{"trials":1587,"activeCount":100},[],{"trials":1589,"activeCount":100},[],{"trials":1591,"activeCount":100},[1592],{"nctId":1548,"briefTitle":1549,"status":574,"phases":1593,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":1553,"conditions":1594,"interventions":1595},[90],[1555],[1537,1557,1558,1559],{"trials":1597,"activeCount":100},[],{"trials":1599,"activeCount":100},[],{"intervention":1559,"totalTrials":133,"cells":1601},{"EARLY_PHASE1":1602,"PHASE1":1604,"PHASE2":1606,"PHASE3":1608,"PHASE4":1614,"NA":1616},{"trials":1603,"activeCount":100},[],{"trials":1605,"activeCount":100},[],{"trials":1607,"activeCount":100},[],{"trials":1609,"activeCount":100},[1610],{"nctId":1548,"briefTitle":1549,"status":574,"phases":1611,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":1553,"conditions":1612,"interventions":1613},[90],[1555],[1537,1557,1558,1559],{"trials":1615,"activeCount":100},[],{"trials":1617,"activeCount":100},[],{"intervention":1329,"totalTrials":133,"cells":1619},{"EARLY_PHASE1":1620,"PHASE1":1622,"PHASE2":1624,"PHASE3":1626,"PHASE4":1632,"NA":1634},{"trials":1621,"activeCount":100},[],{"trials":1623,"activeCount":100},[],{"trials":1625,"activeCount":100},[],{"trials":1627,"activeCount":100},[1628],{"nctId":1319,"briefTitle":1320,"status":123,"phases":1629,"primaryCompletion":1322,"completion":1323,"start":1324,"enrollment":1325,"conditions":1630,"interventions":1631},[89,90],[18,1327],[1308,1329],{"trials":1633,"activeCount":100},[],{"trials":1635,"activeCount":100},[],{"intervention":1637,"totalTrials":133,"cells":1638},"Betamethasone",{"EARLY_PHASE1":1639,"PHASE1":1641,"PHASE2":1643,"PHASE3":1645,"PHASE4":1658,"NA":1660},{"trials":1640,"activeCount":100},[],{"trials":1642,"activeCount":100},[],{"trials":1644,"activeCount":100},[],{"trials":1646,"activeCount":100},[1647],{"nctId":1648,"briefTitle":1649,"status":574,"phases":1650,"primaryCompletion":1651,"completion":1651,"start":1652,"enrollment":1653,"conditions":1654,"interventions":1657},"NCT02939742","Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity?",[89,90],"2023-12-20","2016-11",33,[1655,1656],"PPROM","Respiratory Distress Syndrome in Premature Infants",[1637],{"trials":1659,"activeCount":100},[],{"trials":1661,"activeCount":100},[],{"intervention":1663,"totalTrials":133,"cells":1664},"Amnion",{"EARLY_PHASE1":1665,"PHASE1":1667,"PHASE2":1669,"PHASE3":1671,"PHASE4":1682,"NA":1684},{"trials":1666,"activeCount":100},[],{"trials":1668,"activeCount":100},[],{"trials":1670,"activeCount":100},[],{"trials":1672,"activeCount":100},[1673],{"nctId":1674,"briefTitle":1675,"status":252,"phases":1676,"primaryCompletion":1677,"completion":1677,"start":1678,"enrollment":100,"conditions":1679,"interventions":1680},"NCT00674999","Use of Amnion on Partial Thickness Burns",[89,90],"2008-09","2005-06",[21],[1663,1663,1681],"Polysporin\u002FBacitracin\u002FMycostatin",{"trials":1683,"activeCount":100},[],{"trials":1685,"activeCount":100},[],{"intervention":1681,"totalTrials":133,"cells":1687},{"EARLY_PHASE1":1688,"PHASE1":1690,"PHASE2":1692,"PHASE3":1694,"PHASE4":1700,"NA":1702},{"trials":1689,"activeCount":100},[],{"trials":1691,"activeCount":100},[],{"trials":1693,"activeCount":100},[],{"trials":1695,"activeCount":100},[1696],{"nctId":1674,"briefTitle":1675,"status":252,"phases":1697,"primaryCompletion":1677,"completion":1677,"start":1678,"enrollment":100,"conditions":1698,"interventions":1699},[89,90],[21],[1663,1663,1681],{"trials":1701,"activeCount":100},[],{"trials":1703,"activeCount":100},[],{"intervention":1705,"totalTrials":133,"cells":1706},"Tetracycline",{"EARLY_PHASE1":1707,"PHASE1":1709,"PHASE2":1711,"PHASE3":1713,"PHASE4":1724,"NA":1726},{"trials":1708,"activeCount":100},[],{"trials":1710,"activeCount":100},[],{"trials":1712,"activeCount":100},[],{"trials":1714,"activeCount":100},[1715],{"nctId":1716,"briefTitle":1717,"status":574,"phases":1718,"primaryCompletion":1719,"completion":1719,"start":1720,"enrollment":1721,"conditions":1722,"interventions":1723},"NCT00591162","Bone Disease in Severely Burned Children",[89,90],"2008-06","1992-10",254,[21],[1705],{"trials":1725,"activeCount":100},[],{"trials":1727,"activeCount":100},[],{"intervention":1267,"totalTrials":133,"cells":1729},{"EARLY_PHASE1":1730,"PHASE1":1732,"PHASE2":1734,"PHASE3":1736,"PHASE4":1742,"NA":1744},{"trials":1731,"activeCount":100},[],{"trials":1733,"activeCount":100},[],{"trials":1735,"activeCount":100},[],{"trials":1737,"activeCount":100},[1738],{"nctId":1258,"briefTitle":1259,"status":123,"phases":1739,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1264,"conditions":1740,"interventions":1741},[89,90],[18],[1267,1268,661,269,1269,1270,1271,1272,1273],{"trials":1743,"activeCount":100},[],{"trials":1745,"activeCount":100},[],{"intervention":1269,"totalTrials":133,"cells":1747},{"EARLY_PHASE1":1748,"PHASE1":1750,"PHASE2":1752,"PHASE3":1754,"PHASE4":1760,"NA":1762},{"trials":1749,"activeCount":100},[],{"trials":1751,"activeCount":100},[],{"trials":1753,"activeCount":100},[],{"trials":1755,"activeCount":100},[1756],{"nctId":1258,"briefTitle":1259,"status":123,"phases":1757,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1264,"conditions":1758,"interventions":1759},[89,90],[18],[1267,1268,661,269,1269,1270,1271,1272,1273],{"trials":1761,"activeCount":100},[],{"trials":1763,"activeCount":100},[],{"intervention":1270,"totalTrials":133,"cells":1765},{"EARLY_PHASE1":1766,"PHASE1":1768,"PHASE2":1770,"PHASE3":1772,"PHASE4":1778,"NA":1780},{"trials":1767,"activeCount":100},[],{"trials":1769,"activeCount":100},[],{"trials":1771,"activeCount":100},[],{"trials":1773,"activeCount":100},[1774],{"nctId":1258,"briefTitle":1259,"status":123,"phases":1775,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1264,"conditions":1776,"interventions":1777},[89,90],[18],[1267,1268,661,269,1269,1270,1271,1272,1273],{"trials":1779,"activeCount":100},[],{"trials":1781,"activeCount":100},[],{"intervention":1271,"totalTrials":133,"cells":1783},{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1788,"PHASE3":1790,"PHASE4":1796,"NA":1798},{"trials":1785,"activeCount":100},[],{"trials":1787,"activeCount":100},[],{"trials":1789,"activeCount":100},[],{"trials":1791,"activeCount":100},[1792],{"nctId":1258,"briefTitle":1259,"status":123,"phases":1793,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1264,"conditions":1794,"interventions":1795},[89,90],[18],[1267,1268,661,269,1269,1270,1271,1272,1273],{"trials":1797,"activeCount":100},[],{"trials":1799,"activeCount":100},[],{"intervention":1272,"totalTrials":133,"cells":1801},{"EARLY_PHASE1":1802,"PHASE1":1804,"PHASE2":1806,"PHASE3":1808,"PHASE4":1814,"NA":1816},{"trials":1803,"activeCount":100},[],{"trials":1805,"activeCount":100},[],{"trials":1807,"activeCount":100},[],{"trials":1809,"activeCount":100},[1810],{"nctId":1258,"briefTitle":1259,"status":123,"phases":1811,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1264,"conditions":1812,"interventions":1813},[89,90],[18],[1267,1268,661,269,1269,1270,1271,1272,1273],{"trials":1815,"activeCount":100},[],{"trials":1817,"activeCount":100},[],{"intervention":1273,"totalTrials":133,"cells":1819},{"EARLY_PHASE1":1820,"PHASE1":1822,"PHASE2":1824,"PHASE3":1826,"PHASE4":1832,"NA":1834},{"trials":1821,"activeCount":100},[],{"trials":1823,"activeCount":100},[],{"trials":1825,"activeCount":100},[],{"trials":1827,"activeCount":100},[1828],{"nctId":1258,"briefTitle":1259,"status":123,"phases":1829,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1264,"conditions":1830,"interventions":1831},[89,90],[18],[1267,1268,661,269,1269,1270,1271,1272,1273],{"trials":1833,"activeCount":100},[],{"trials":1835,"activeCount":100},[],{"intervention":1837,"totalTrials":133,"cells":1838},"Vitamin D",{"EARLY_PHASE1":1839,"PHASE1":1841,"PHASE2":1843,"PHASE3":1845,"PHASE4":1854,"NA":1856},{"trials":1840,"activeCount":100},[],{"trials":1842,"activeCount":100},[],{"trials":1844,"activeCount":100},[],{"trials":1846,"activeCount":100},[1847],{"nctId":1848,"briefTitle":1849,"status":252,"phases":1850,"primaryCompletion":623,"completion":623,"start":1851,"enrollment":100,"conditions":1852,"interventions":1853},"NCT00591604","High-Dose Vitamin D Deficiency in Burn Injury",[90],"2007-02",[21],[1837],{"trials":1855,"activeCount":100},[],{"trials":1857,"activeCount":100},[],{"intervention":1859,"totalTrials":133,"cells":1860},"Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]",{"EARLY_PHASE1":1861,"PHASE1":1863,"PHASE2":1865,"PHASE3":1867,"PHASE4":1876,"NA":1878},{"trials":1862,"activeCount":100},[],{"trials":1864,"activeCount":100},[],{"trials":1866,"activeCount":100},[],{"trials":1868,"activeCount":100},[1869],{"nctId":1870,"briefTitle":1871,"status":252,"phases":1872,"primaryCompletion":1873,"completion":1873,"start":588,"enrollment":100,"conditions":1874,"interventions":1875},"NCT00591916","New Treatment for Donor Sites",[89,90],"2010-11",[21],[1859],{"trials":1877,"activeCount":100},[],{"trials":1879,"activeCount":100},[],{"intervention":1881,"totalTrials":578,"cells":1882},"arsenic trioxide",{"EARLY_PHASE1":1883,"PHASE1":1885,"PHASE2":1887,"PHASE3":1913,"PHASE4":1915,"NA":1917},{"trials":1884,"activeCount":100},[],{"trials":1886,"activeCount":100},[],{"trials":1888,"activeCount":100},[1889,1898,1906],{"nctId":1890,"briefTitle":1891,"status":574,"phases":1892,"primaryCompletion":1893,"completion":1893,"start":1894,"enrollment":25,"conditions":1895,"interventions":1897},"NCT00582400","A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver",[89],"2010-04","2004-09",[1896],"Carcinoma, Hepatocellular",[1881],{"nctId":1899,"briefTitle":1900,"status":252,"phases":1901,"primaryCompletion":1902,"start":1903,"enrollment":100,"conditions":1904,"interventions":1905},"NCT00075413","Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer",[89],"2005-07","2002-11",[24],[1881],{"nctId":1907,"briefTitle":1908,"status":123,"phases":1909,"primaryCompletion":1902,"completion":1902,"start":1903,"enrollment":281,"conditions":1910,"interventions":1912},"NCT00075426","Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[89],[1911],"Lung Cancer",[1881],{"trials":1914,"activeCount":100},[],{"trials":1916,"activeCount":100},[],{"trials":1918,"activeCount":100},[],{"intervention":1920,"totalTrials":133,"cells":1921},"Ketorolac Tromethamine",{"EARLY_PHASE1":1922,"PHASE1":1924,"PHASE2":1926,"PHASE3":1939,"PHASE4":1941,"NA":1943},{"trials":1923,"activeCount":100},[],{"trials":1925,"activeCount":100},[],{"trials":1927,"activeCount":100},[1928],{"nctId":1929,"briefTitle":1930,"status":574,"phases":1931,"primaryCompletion":1932,"completion":1932,"start":1933,"enrollment":133,"conditions":1934,"interventions":1937},"NCT03913702","Subacromial Methylprednisolone Versus Ketorolac for Shoulder Impingement",[89],"2022-11-02","2019-09-09",[1935,1936],"Subacromial Impingement","Subacromial Impingement Syndrome",[1920,1938],"Methylprednisolone Acetate",{"trials":1940,"activeCount":100},[],{"trials":1942,"activeCount":100},[],{"trials":1944,"activeCount":100},[],{"intervention":1938,"totalTrials":133,"cells":1946},{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1957,"PHASE4":1959,"NA":1961},{"trials":1948,"activeCount":100},[],{"trials":1950,"activeCount":100},[],{"trials":1952,"activeCount":100},[1953],{"nctId":1929,"briefTitle":1930,"status":574,"phases":1954,"primaryCompletion":1932,"completion":1932,"start":1933,"enrollment":133,"conditions":1955,"interventions":1956},[89],[1935,1936],[1920,1938],{"trials":1958,"activeCount":100},[],{"trials":1960,"activeCount":100},[],{"trials":1962,"activeCount":100},[],{"intervention":1964,"totalTrials":133,"cells":1965},"Panhematin",{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1970,"PHASE3":1981,"PHASE4":1983,"NA":1985},{"trials":1967,"activeCount":100},[],{"trials":1969,"activeCount":100},[],{"trials":1971,"activeCount":100},[1972],{"nctId":1973,"briefTitle":1974,"status":123,"phases":1975,"primaryCompletion":1976,"completion":1976,"start":558,"enrollment":1977,"conditions":1978,"interventions":1980},"NCT02180412","Controlled Trial of Panhematin in Treatment of Acute Attacks of Porphyria",[89],"2022-02-03",20,[1979],"Acute Porphyrias",[1964],{"trials":1982,"activeCount":100},[],{"trials":1984,"activeCount":100},[],{"trials":1986,"activeCount":100},[],{"intervention":1988,"totalTrials":133,"cells":1989},"Depakote ER",{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1994,"PHASE3":2005,"PHASE4":2007,"NA":2009},{"trials":1991,"activeCount":100},[],{"trials":1993,"activeCount":100},[],{"trials":1995,"activeCount":100},[1996],{"nctId":1997,"briefTitle":1998,"status":252,"phases":1999,"completion":2000,"start":2001,"enrollment":100,"conditions":2002,"interventions":2004},"NCT00204503","Open-Label Depakote ER in Patients With Bipolar I or II Depression and Alcohol Abuse or Dependence",[89],"2005-05","2003-06",[2003],"Bipolar I or II Depression and Alcohol Abuse or Dependence",[1988],{"trials":2006,"activeCount":100},[],{"trials":2008,"activeCount":100},[],{"trials":2010,"activeCount":100},[],{"intervention":2012,"totalTrials":133,"cells":2013},"Hydroxychloroquine",{"EARLY_PHASE1":2014,"PHASE1":2016,"PHASE2":2018,"PHASE3":2029,"PHASE4":2031,"NA":2033},{"trials":2015,"activeCount":100},[],{"trials":2017,"activeCount":100},[],{"trials":2019,"activeCount":100},[2020],{"nctId":2021,"briefTitle":2022,"status":123,"phases":2023,"primaryCompletion":2024,"completion":2024,"start":2025,"enrollment":480,"conditions":2026,"interventions":2028},"NCT01573754","Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda",[89],"2021-07-06","2006-03-21",[2027],"Porphyria Cutanea Tarda",[2012],{"trials":2030,"activeCount":100},[],{"trials":2032,"activeCount":100},[],{"trials":2034,"activeCount":100},[],{"intervention":2036,"totalTrials":133,"cells":2037},"Labetalol",{"EARLY_PHASE1":2038,"PHASE1":2040,"PHASE2":2042,"PHASE3":2055,"PHASE4":2057,"NA":2059},{"trials":2039,"activeCount":100},[],{"trials":2041,"activeCount":100},[],{"trials":2043,"activeCount":100},[2044],{"nctId":2045,"briefTitle":2046,"status":123,"phases":2047,"primaryCompletion":2048,"completion":2048,"start":2049,"enrollment":2050,"conditions":2051,"interventions":2053},"NCT03661346","Esmolol vs. Labetalol in Endoscopic Sinus Surgery",[89],"2018-03-30","2017-03-01",28,[2052],"Chronic Sinusitis",[2036,2054],"Esmolol",{"trials":2056,"activeCount":100},[],{"trials":2058,"activeCount":100},[],{"trials":2060,"activeCount":100},[],{"intervention":2054,"totalTrials":133,"cells":2062},{"EARLY_PHASE1":2063,"PHASE1":2065,"PHASE2":2067,"PHASE3":2073,"PHASE4":2075,"NA":2077},{"trials":2064,"activeCount":100},[],{"trials":2066,"activeCount":100},[],{"trials":2068,"activeCount":100},[2069],{"nctId":2045,"briefTitle":2046,"status":123,"phases":2070,"primaryCompletion":2048,"completion":2048,"start":2049,"enrollment":2050,"conditions":2071,"interventions":2072},[89],[2052],[2036,2054],{"trials":2074,"activeCount":100},[],{"trials":2076,"activeCount":100},[],{"trials":2078,"activeCount":100},[],{"intervention":2080,"totalTrials":133,"cells":2081},"N-acetylcysteine",{"EARLY_PHASE1":2082,"PHASE1":2084,"PHASE2":2086,"PHASE3":2096,"PHASE4":2098,"NA":2100},{"trials":2083,"activeCount":100},[],{"trials":2085,"activeCount":100},[],{"trials":2087,"activeCount":100},[2088],{"nctId":2089,"briefTitle":2090,"status":123,"phases":2091,"primaryCompletion":2092,"completion":2092,"start":840,"enrollment":36,"conditions":2093,"interventions":2094},"NCT01384591","Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly",[88,89],"2015-05",[15],[2080,2095],"Losartan",{"trials":2097,"activeCount":100},[],{"trials":2099,"activeCount":100},[],{"trials":2101,"activeCount":100},[],{"intervention":2095,"totalTrials":133,"cells":2103},{"EARLY_PHASE1":2104,"PHASE1":2106,"PHASE2":2108,"PHASE3":2114,"PHASE4":2116,"NA":2118},{"trials":2105,"activeCount":100},[],{"trials":2107,"activeCount":100},[],{"trials":2109,"activeCount":100},[2110],{"nctId":2089,"briefTitle":2090,"status":123,"phases":2111,"primaryCompletion":2092,"completion":2092,"start":840,"enrollment":36,"conditions":2112,"interventions":2113},[88,89],[15],[2080,2095],{"trials":2115,"activeCount":100},[],{"trials":2117,"activeCount":100},[],{"trials":2119,"activeCount":100},[],{"intervention":2121,"totalTrials":133,"cells":2122},"Hemin for",{"EARLY_PHASE1":2123,"PHASE1":2125,"PHASE2":2127,"PHASE3":2137,"PHASE4":2139,"NA":2141},{"trials":2124,"activeCount":100},[],{"trials":2126,"activeCount":100},[],{"trials":2128,"activeCount":100},[2129],{"nctId":2130,"briefTitle":2131,"status":574,"phases":2132,"primaryCompletion":2133,"completion":2133,"start":2134,"enrollment":1325,"conditions":2135,"interventions":2136},"NCT02922413","Panhematin for Prevention of Acute Attacks of Porphyria",[89],"2023-12-27","2015-10-30",[561,562,563],[2121],{"trials":2138,"activeCount":100},[],{"trials":2140,"activeCount":100},[],{"trials":2142,"activeCount":100},[],{"intervention":2144,"totalTrials":133,"cells":2145},"carcinoembryonic antigen peptide 1-6D",{"EARLY_PHASE1":2146,"PHASE1":2148,"PHASE2":2150,"PHASE3":2168,"PHASE4":2170,"NA":2172},{"trials":2147,"activeCount":100},[],{"trials":2149,"activeCount":100},[],{"trials":2151,"activeCount":100},[2152],{"nctId":2153,"briefTitle":2154,"status":574,"phases":2155,"primaryCompletion":2156,"completion":2156,"start":2157,"enrollment":33,"conditions":2158,"interventions":2165},"NCT00012246","Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract",[89],"2006-07","2002-07",[2159,2160,2161,2162,2163,257,2164],"Colorectal Cancer","Esophageal Cancer","Extrahepatic Bile Duct Cancer","Gallbladder Cancer","Gastric Cancer","Small Intestine Cancer",[2144,2166,2167],"incomplete Freund's adjuvant","sargramostim",{"trials":2169,"activeCount":100},[],{"trials":2171,"activeCount":100},[],{"trials":2173,"activeCount":100},[],{"intervention":2166,"totalTrials":133,"cells":2175},{"EARLY_PHASE1":2176,"PHASE1":2178,"PHASE2":2180,"PHASE3":2186,"PHASE4":2188,"NA":2190},{"trials":2177,"activeCount":100},[],{"trials":2179,"activeCount":100},[],{"trials":2181,"activeCount":100},[2182],{"nctId":2153,"briefTitle":2154,"status":574,"phases":2183,"primaryCompletion":2156,"completion":2156,"start":2157,"enrollment":33,"conditions":2184,"interventions":2185},[89],[2159,2160,2161,2162,2163,257,2164],[2144,2166,2167],{"trials":2187,"activeCount":100},[],{"trials":2189,"activeCount":100},[],{"trials":2191,"activeCount":100},[],{"intervention":2167,"totalTrials":133,"cells":2193},{"EARLY_PHASE1":2194,"PHASE1":2196,"PHASE2":2198,"PHASE3":2204,"PHASE4":2206,"NA":2208},{"trials":2195,"activeCount":100},[],{"trials":2197,"activeCount":100},[],{"trials":2199,"activeCount":100},[2200],{"nctId":2153,"briefTitle":2154,"status":574,"phases":2201,"primaryCompletion":2156,"completion":2156,"start":2157,"enrollment":33,"conditions":2202,"interventions":2203},[89],[2159,2160,2161,2162,2163,257,2164],[2144,2166,2167],{"trials":2205,"activeCount":100},[],{"trials":2207,"activeCount":100},[],{"trials":2209,"activeCount":100},[],{"intervention":2211,"totalTrials":578,"cells":2212},"Sodium Nitroprusside",{"EARLY_PHASE1":2213,"PHASE1":2215,"PHASE2":2247,"PHASE3":2249,"PHASE4":2251,"NA":2253},{"trials":2214,"activeCount":100},[],{"trials":2216,"activeCount":100},[2217,2227,2238],{"nctId":2218,"briefTitle":2219,"status":123,"phases":2220,"primaryCompletion":2221,"completion":2221,"start":2222,"enrollment":320,"conditions":2223,"interventions":2224},"NCT00891696","Nutritional and Contractile Regulation of Muscle Growth",[88],"2015-03","2009-04",[27],[2225,2226],"Rapamycin","Sodium nitroprusside",{"nctId":2228,"briefTitle":2229,"status":123,"phases":2230,"primaryCompletion":2231,"completion":2231,"start":2232,"enrollment":2233,"conditions":2234,"interventions":2235},"NCT00690534","Insulin and Sarcopenia in the Elderly",[88],"2012-08","2005-09",88,[27],[2236,2237,2211],"Insulin Regular","L-NMMA",{"nctId":2239,"briefTitle":2240,"status":123,"phases":2241,"primaryCompletion":1527,"completion":2242,"start":2243,"enrollment":2244,"conditions":2245,"interventions":2246},"NCT00945256","Muscle Perfusion and Protein Metabolism in Elderly",[88],"2009-05","2003-05",62,[15],[2211],{"trials":2248,"activeCount":100},[],{"trials":2250,"activeCount":100},[],{"trials":2252,"activeCount":100},[],{"trials":2254,"activeCount":100},[],{"intervention":2256,"totalTrials":96,"cells":2257},"Metronidazole",{"EARLY_PHASE1":2258,"PHASE1":2260,"PHASE2":2281,"PHASE3":2283,"PHASE4":2285,"NA":2287},{"trials":2259,"activeCount":100},[],{"trials":2261,"activeCount":100},[2262,2272],{"nctId":2263,"briefTitle":2264,"status":123,"phases":2265,"primaryCompletion":2266,"completion":2266,"start":2267,"enrollment":2268,"conditions":2269,"interventions":2270},"NCT03187106","Prophylactic Antibiotics After Cesarean",[88],"2023-07-21","2017-08-01",321,[950],[2271,2256],"Cephalexin",{"nctId":2273,"briefTitle":2274,"status":574,"phases":2275,"primaryCompletion":2276,"completion":2276,"start":2277,"enrollment":367,"conditions":2278,"interventions":2280},"NCT03954990","Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity",[88],"2022-09-26","2019-10-11",[2279],"Bacterial Vaginoses",[2256],{"trials":2282,"activeCount":100},[],{"trials":2284,"activeCount":100},[],{"trials":2286,"activeCount":100},[],{"trials":2288,"activeCount":100},[],{"intervention":2290,"totalTrials":133,"cells":2291},"Testosterone Enanthate 100 MG\u002FML",{"EARLY_PHASE1":2292,"PHASE1":2294,"PHASE2":2306,"PHASE3":2308,"PHASE4":2310,"NA":2312},{"trials":2293,"activeCount":100},[],{"trials":2295,"activeCount":100},[2296],{"nctId":2297,"briefTitle":2298,"status":123,"phases":2299,"primaryCompletion":2300,"completion":293,"start":2301,"enrollment":2050,"conditions":2302,"interventions":2305},"NCT00878995","Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma",[88],"2014-06","2009-06-03",[2303,2304],"Cachexia","Squamous Cell Carcinoma",[2290],{"trials":2307,"activeCount":100},[],{"trials":2309,"activeCount":100},[],{"trials":2311,"activeCount":100},[],{"trials":2313,"activeCount":100},[],{"intervention":2315,"totalTrials":133,"cells":2316},"Growth Hormone Releasing Hormone",{"EARLY_PHASE1":2317,"PHASE1":2319,"PHASE2":2331,"PHASE3":2333,"PHASE4":2335,"NA":2337},{"trials":2318,"activeCount":100},[],{"trials":2320,"activeCount":100},[2321],{"nctId":2322,"briefTitle":2323,"status":123,"phases":2324,"primaryCompletion":2325,"completion":2325,"start":2326,"enrollment":2327,"conditions":2328,"interventions":2330},"NCT02553603","The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment",[88],"2019-01-17","2017-07-18",22,[2329],"Mild Cognitive Impairment",[2315],{"trials":2332,"activeCount":100},[],{"trials":2334,"activeCount":100},[],{"trials":2336,"activeCount":100},[],{"trials":2338,"activeCount":100},[],{"intervention":2340,"totalTrials":133,"cells":2341},"Coenzyme Q10",{"EARLY_PHASE1":2342,"PHASE1":2344,"PHASE2":2355,"PHASE3":2357,"PHASE4":2359,"NA":2361},{"trials":2343,"activeCount":100},[],{"trials":2345,"activeCount":100},[2346],{"nctId":2347,"briefTitle":2348,"status":123,"phases":2349,"primaryCompletion":2350,"completion":2350,"start":2351,"enrollment":133,"conditions":2352,"interventions":2354},"NCT00957216","Coenzyme Q10 in Adult-Onset Ataxia",[88],"2009-08","2008-04",[2353],"Sporadic Ataxia",[2340],{"trials":2356,"activeCount":100},[],{"trials":2358,"activeCount":100},[],{"trials":2360,"activeCount":100},[],{"trials":2362,"activeCount":100},[],{"intervention":2364,"totalTrials":133,"cells":2365},"Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14",{"EARLY_PHASE1":2366,"PHASE1":2368,"PHASE2":2379,"PHASE3":2381,"PHASE4":2383,"NA":2385},{"trials":2367,"activeCount":100},[],{"trials":2369,"activeCount":100},[2370],{"nctId":2371,"briefTitle":2372,"status":123,"phases":2373,"primaryCompletion":2221,"completion":2221,"start":2374,"enrollment":2375,"conditions":2376,"interventions":2378},"NCT04638257","Role of Oral Lactobacilli on Vaginal Flora of Pregnant Women",[88],"2013-01",49,[2377],"Bacterial Vaginosis",[2364],{"trials":2380,"activeCount":100},[],{"trials":2382,"activeCount":100},[],{"trials":2384,"activeCount":100},[],{"trials":2386,"activeCount":100},[],{"intervention":2388,"totalTrials":133,"cells":2389},"Pravastatin",{"EARLY_PHASE1":2390,"PHASE1":2392,"PHASE2":2402,"PHASE3":2404,"PHASE4":2406,"NA":2408},{"trials":2391,"activeCount":100},[],{"trials":2393,"activeCount":100},[2394],{"nctId":2395,"briefTitle":2396,"status":123,"phases":2397,"primaryCompletion":2398,"completion":2398,"start":2231,"enrollment":480,"conditions":2399,"interventions":2401},"NCT01717586","Pravastatin for Prevention of Preeclampsia",[88],"2024-02-12",[2400],"Preeclampsia",[2388],{"trials":2403,"activeCount":100},[],{"trials":2405,"activeCount":100},[],{"trials":2407,"activeCount":100},[],{"trials":2409,"activeCount":100},[],{"intervention":2411,"totalTrials":133,"cells":2412},"L-citrulline",{"EARLY_PHASE1":2413,"PHASE1":2415,"PHASE2":2429,"PHASE3":2431,"PHASE4":2433,"NA":2435},{"trials":2414,"activeCount":100},[],{"trials":2416,"activeCount":100},[2417],{"nctId":2418,"briefTitle":2419,"status":2420,"phases":2421,"primaryCompletion":2422,"completion":2422,"start":2423,"enrollment":2424,"conditions":2425,"interventions":2428},"NCT04979793","Role of L-citrulline in Prevention of Pregnancy Associated Hypertension","SUSPENDED",[88],"2027-07-30","2021-07-28",338,[2426,2427,1412],"Pregnancy Induced Hypertension","Preeclampsia and Eclampsia",[2411],{"trials":2430,"activeCount":100},[],{"trials":2432,"activeCount":100},[],{"trials":2434,"activeCount":100},[],{"trials":2436,"activeCount":100},[],{"intervention":2271,"totalTrials":133,"cells":2438},{"EARLY_PHASE1":2439,"PHASE1":2441,"PHASE2":2447,"PHASE3":2449,"PHASE4":2451,"NA":2453},{"trials":2440,"activeCount":100},[],{"trials":2442,"activeCount":100},[2443],{"nctId":2263,"briefTitle":2264,"status":123,"phases":2444,"primaryCompletion":2266,"completion":2266,"start":2267,"enrollment":2268,"conditions":2445,"interventions":2446},[88],[950],[2271,2256],{"trials":2448,"activeCount":100},[],{"trials":2450,"activeCount":100},[],{"trials":2452,"activeCount":100},[],{"trials":2454,"activeCount":100},[],{"intervention":2456,"totalTrials":133,"cells":2457},"tetrahydrobiopterin",{"EARLY_PHASE1":2458,"PHASE1":2460,"PHASE2":2472,"PHASE3":2474,"PHASE4":2476,"NA":2478},{"trials":2459,"activeCount":100},[],{"trials":2461,"activeCount":100},[2462],{"nctId":2463,"briefTitle":2464,"status":574,"phases":2465,"primaryCompletion":623,"completion":2466,"start":2467,"enrollment":2468,"conditions":2469,"interventions":2471},"NCT00244218","Response to Phenylketonuria to Tetrahydrobiopterin (BH4)",[88],"2015-01","2005-04",57,[2470],"Phenylketonuria",[2456],{"trials":2473,"activeCount":100},[],{"trials":2475,"activeCount":100},[],{"trials":2477,"activeCount":100},[],{"trials":2479,"activeCount":100},[],{"intervention":2481,"totalTrials":133,"cells":2482},"Exercise",{"EARLY_PHASE1":2483,"PHASE1":2485,"PHASE2":2495,"PHASE3":2497,"PHASE4":2499,"NA":2501},{"trials":2484,"activeCount":100},[],{"trials":2486,"activeCount":100},[2487],{"nctId":2488,"briefTitle":2489,"status":123,"phases":2490,"primaryCompletion":2491,"completion":2492,"start":623,"enrollment":532,"conditions":2493,"interventions":2494},"NCT00872911","Nutrition and Exercise for Sarcopenia",[88],"2014-12","2016-08",[27],[2481],{"trials":2496,"activeCount":100},[],{"trials":2498,"activeCount":100},[],{"trials":2500,"activeCount":100},[],{"trials":2502,"activeCount":100},[],{"intervention":2225,"totalTrials":133,"cells":2504},{"EARLY_PHASE1":2505,"PHASE1":2507,"PHASE2":2513,"PHASE3":2515,"PHASE4":2517,"NA":2519},{"trials":2506,"activeCount":100},[],{"trials":2508,"activeCount":100},[2509],{"nctId":2218,"briefTitle":2219,"status":123,"phases":2510,"primaryCompletion":2221,"completion":2221,"start":2222,"enrollment":320,"conditions":2511,"interventions":2512},[88],[27],[2225,2226],{"trials":2514,"activeCount":100},[],{"trials":2516,"activeCount":100},[],{"trials":2518,"activeCount":100},[],{"trials":2520,"activeCount":100},[],{"intervention":2522,"totalTrials":133,"cells":2523},"ragweed pollen",{"EARLY_PHASE1":2524,"PHASE1":2526,"PHASE2":2536,"PHASE3":2538,"PHASE4":2540,"NA":2542},{"trials":2525,"activeCount":100},[],{"trials":2527,"activeCount":100},[2528],{"nctId":2529,"briefTitle":2530,"status":123,"phases":2531,"primaryCompletion":2532,"completion":2532,"start":2533,"enrollment":624,"conditions":2534,"interventions":2535},"NCT03496103","Innate Neutrophilic Nasal Inflammation in a Pollen Exposure Chamber",[88],"2016-03-12","2016-02-29",[370],[2522],{"trials":2537,"activeCount":100},[],{"trials":2539,"activeCount":100},[],{"trials":2541,"activeCount":100},[],{"trials":2543,"activeCount":100},[],{"intervention":2236,"totalTrials":133,"cells":2545},{"EARLY_PHASE1":2546,"PHASE1":2548,"PHASE2":2554,"PHASE3":2556,"PHASE4":2558,"NA":2560},{"trials":2547,"activeCount":100},[],{"trials":2549,"activeCount":100},[2550],{"nctId":2228,"briefTitle":2229,"status":123,"phases":2551,"primaryCompletion":2231,"completion":2231,"start":2232,"enrollment":2233,"conditions":2552,"interventions":2553},[88],[27],[2236,2237,2211],{"trials":2555,"activeCount":100},[],{"trials":2557,"activeCount":100},[],{"trials":2559,"activeCount":100},[],{"trials":2561,"activeCount":100},[],{"intervention":2237,"totalTrials":133,"cells":2563},{"EARLY_PHASE1":2564,"PHASE1":2566,"PHASE2":2572,"PHASE3":2574,"PHASE4":2576,"NA":2578},{"trials":2565,"activeCount":100},[],{"trials":2567,"activeCount":100},[2568],{"nctId":2228,"briefTitle":2229,"status":123,"phases":2569,"primaryCompletion":2231,"completion":2231,"start":2232,"enrollment":2233,"conditions":2570,"interventions":2571},[88],[27],[2236,2237,2211],{"trials":2573,"activeCount":100},[],{"trials":2575,"activeCount":100},[],{"trials":2577,"activeCount":100},[],{"trials":2579,"activeCount":100},[],{"intervention":2581,"totalTrials":133,"cells":2582},"Proflavine",{"EARLY_PHASE1":2583,"PHASE1":2595,"PHASE2":2597,"PHASE3":2599,"PHASE4":2601,"NA":2603},{"trials":2584,"activeCount":100},[2585],{"nctId":2586,"briefTitle":2587,"status":574,"phases":2588,"primaryCompletion":2589,"completion":2589,"start":2590,"enrollment":2591,"conditions":2592,"interventions":2594},"NCT02714439","Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley",[87],"2024-02-09","2016-10-25",157,[2593],"Malignant Neoplasms of Female Genital Organs",[2581],{"trials":2596,"activeCount":100},[],{"trials":2598,"activeCount":100},[],{"trials":2600,"activeCount":100},[],{"trials":2602,"activeCount":100},[],{"trials":2604,"activeCount":100},[],{"intervention":2606,"totalTrials":133,"cells":2607},"Ofiramev®",{"EARLY_PHASE1":2608,"PHASE1":2610,"PHASE2":2612,"PHASE3":2614,"PHASE4":2616,"NA":2618},{"trials":2609,"activeCount":100},[],{"trials":2611,"activeCount":100},[],{"trials":2613,"activeCount":100},[],{"trials":2615,"activeCount":100},[],{"trials":2617,"activeCount":100},[],{"trials":2619,"activeCount":100},[2620],{"nctId":2621,"briefTitle":2622,"status":252,"phases":2623,"primaryCompletion":2624,"completion":2624,"start":2625,"enrollment":100,"conditions":2626,"interventions":2628},"NCT03051932","Effects of Intravenous Acetaminophen in Patients Undergoing Thoracoscopic Surgery",[92],"2019-06-01","2018-06-01",[2627],"Post-thoracotomy Pain Syndrome",[2606],{"intervention":2630,"totalTrials":133,"cells":2631},"clonidine",{"EARLY_PHASE1":2632,"PHASE1":2634,"PHASE2":2636,"PHASE3":2638,"PHASE4":2640,"NA":2642},{"trials":2633,"activeCount":100},[],{"trials":2635,"activeCount":100},[],{"trials":2637,"activeCount":100},[],{"trials":2639,"activeCount":100},[],{"trials":2641,"activeCount":100},[],{"trials":2643,"activeCount":100},[2644],{"nctId":2645,"briefTitle":2646,"status":574,"phases":2647,"primaryCompletion":2300,"completion":2300,"start":2648,"enrollment":25,"conditions":2649,"interventions":2651},"NCT00580151","The Use of Clonidine in Pain and Anxiety Associated With Acute Burn Injury in Children",[92],"2004-06",[868,2650],"Anxiety",[2630],{"intervention":2653,"totalTrials":133,"cells":2654},"Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks",{"EARLY_PHASE1":2655,"PHASE1":2657,"PHASE2":2659,"PHASE3":2661,"PHASE4":2663,"NA":2665},{"trials":2656,"activeCount":100},[],{"trials":2658,"activeCount":100},[],{"trials":2660,"activeCount":100},[],{"trials":2662,"activeCount":100},[],{"trials":2664,"activeCount":100},[],{"trials":2666,"activeCount":100},[2667],{"nctId":2668,"briefTitle":2669,"status":252,"phases":2670,"primaryCompletion":2671,"completion":2671,"start":2672,"enrollment":100,"conditions":2673,"interventions":2675},"NCT01377961","Effect of Lycopene and Isoflavones on Glucose Metabolism",[92],"2015-08","2010-09",[1015,2674],"Diabetes Mellitus, Non-Insulin-Dependent",[2653],{"intervention":298,"totalTrials":133,"cells":2677},{"EARLY_PHASE1":2678,"PHASE1":2680,"PHASE2":2682,"PHASE3":2684,"PHASE4":2686,"NA":2688},{"trials":2679,"activeCount":100},[],{"trials":2681,"activeCount":100},[],{"trials":2683,"activeCount":100},[],{"trials":2685,"activeCount":100},[],{"trials":2687,"activeCount":100},[],{"trials":2689,"activeCount":100},[2690],{"nctId":290,"briefTitle":291,"status":123,"phases":2691,"primaryCompletion":293,"completion":293,"start":294,"enrollment":281,"conditions":2692,"interventions":2693},[92],[296],[42,298]]